Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common bleeding drug cut transfusions after hip fractures?

NCT ID NCT03063892

Ongoing Disease control Sponsor: Gregory M Georgiadis MD Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether tranexamic acid (TXA), a drug that helps control bleeding, can reduce the need for blood transfusions in people over 60 who have hip fractures and require surgery. Participants receive either TXA or a placebo (saline) before, during, and after surgery. The study measures how many patients need a blood transfusion and how much blood is lost during the operation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tranexamic acid (TXA)
What this could lead to
If it works, this could reduce the need for blood transfusions after hip fracture surgery, lowering risks and recovery time.
What could go wrong
This is a small, early-phase trial. TXA may not reduce transfusions significantly, and there is a small risk of blood clots or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIP FRACTURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hip fracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIP FRACTURES

Contacts and locations

Locations

  • ProMedica Toledo Hospital

    Toledo, Ohio, 43606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.